The Journey of Eli Lilly Stock
Amid the tumultuous ebbs and flows of the stock market, Eli Lilly stock (NYSE: LLY) has emerged as a beacon of prosperity, soaring a remarkable 345% from $170 in 2021 to around $755 today. The company’s monumental surge, climbing 236% in its P/S ratio to 21x over three years, has left the S&P 500 trailing with a mere 35% increase over the same period. Investors have fervently backed LLY stock, entranced by its robust pipeline potential, particularly in the realm of obesity drugs.
Peerless Performance in a Volatile Market
In a trading landscape fraught with uncertainties, LLY stock stood as a steadfast victor, outshining the broader market year after year. From a stellar 64% return in 2021 to a resilient 59% in 2023, Eli Lilly has consistently outpaced the S&P 500, proving its mettle even in the face of adversities.
The Enigma of Consistent Excellence
As the stock market remains a treacherous terrain for many, Eli Lilly’s consistent outperformance shines as a rare gem amidst the Health Care sector giants. Contrastingly, even megacap juggernauts such as UNH, JNJ, and ABBV, alongside tech titans like GOOG, TSLA, and MSFT, have struggled to replicate this feat. However, the Trefis High Quality (HQ) Portfolio, comprising 30 select stocks, has consistently outshined the S&P 500 year after year, beckoning the question – what’s the secret behind this continuous triumph?
The Road Ahead amidst Uncertainty
Amidst the tumultuous macroeconomic environment reeling from high oil prices and escalating interest rates, the prospect of Eli Lilly’s future valuation looms large. With its worth hinging significantly on forthcoming pipeline potential rather than current earnings, analysts’ projection of an $800 average, around 6% above its prevailing market value of $750, paints a positive picture.
Achieving New Milestones
Eli Lilly’s revenue trajectory reads like a saga of triumph, scaling a remarkable 39% from $35 billion in 2020 to $34 billion in 2023. Bolstered by market share strides in key drugs such as Mounjaro, Verzenio, and Zyprexa, the company’s forthcoming diabetes drug Mounjaro, set to amass $33 billion in annual sales by 2029, promises a bright future. Underscoring this success is Zepbound, Eli Lilly’s obesity drug, capturing FDA approval last year and projected to rake in over $16 billion annually by 2029.
